News
MarketBeat on MSN3h
Nektar Jumps 157% on Drug Trial Data-Can It Go Even Higher?Nektar Therapeutics (NASDAQ: NKTR) stock exploded nearly 157% following news that Rezpeg, the company’s experimental ...
Learn how Dupixent helps diverse eczema patients and why inclusive clinical trials are vital for fair healthcare.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback